Back to BNN.DEView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Depressive Disorder, Major
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA10/17/2003
Onsenal
Onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance (see section 4.4). The effect of Onsenal-induced reduction of polyp burden on the risk of intestinal cancer has not been demonstrated (see sections 4.4 and 5.1)
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Escitalopram oxalatePhase 3
Major Depressive Disorder
Nerinetide (NA-1)Phase 3
Acute Cerebral Ischemia
ProgesteronePhase 3
Alcohol Dependence
Inhaled isoflurane administered by Sedaconda ACD-SPhase 3
Post-Intensive Care Syndrome
0.5 mgTestosterone + 10 mg BuspironePhase 2
Hypoactive Sexual Desire Disorder
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts